Aster DM Healthcare Limited has achieved a significant milestone in its proposed merger with Quality Care India Limited, securing overwhelming approval from both shareholders and creditors. The company received 96.68% voting approval from shareholders along with unanimous creditor support during meetings held on March 10, 2026.

Shareholder and Creditor Approval Results

The meetings, conducted through Video Conferencing and Other Audio Visual Means pursuant to Hon'ble National Company Law Tribunal (NCLT) directions, demonstrated strong stakeholder confidence in the strategic merger. The approval reflects broad-based investor support for the share swap preceding the merger.

Meeting Proceedings and Process

The creditors meeting was chaired by Ms. K V S. Madhumita, Advocate, with Mr. Mohit Kumar Goyal, Practicing Company Secretary, serving as the NCLT-appointed scrutinizer. The comprehensive voting process included both remote e-voting from March 6-9, 2026, and electronic voting during the meeting.

Strategic Impact and Combined Entity

Dr. Azad Moopen, Founder Chairman of Aster DM Healthcare, emphasized the strategic value of the merger, stating that the strong shareholder support reflects confidence in the long-term value creation potential. The merger combines Aster's patient-centric care approach with institutional strength and growth expertise. The combined entity will rank among India's top three hospital chains with more than 10,625 beds nationwide.

Regulatory Compliance and Timeline

The company has fulfilled regulatory requirements under the Companies Act, 2013 and SEBI Listing Regulations. The voting results and consolidated scrutinizer's report have been disclosed to stock exchanges pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The merger completion is expected in the next quarter, pending remaining regulatory and statutory NCLT approvals.

The transaction had previously received Competition Commission of India (CCI) and Stock Exchange approvals, marking significant progress in the regulatory approval process for this strategic healthcare sector consolidation.

Aster DM Healthcare Limited has announced a shareholder meeting scheduled for March 10, 2026, to approve its proposed scheme of amalgamation with Quality Care India Limited. The meeting represents a crucial step in what the company describes as the largest transaction in India's hospital sector, with strong shareholder support backing the strategic merger.

Meeting Details and Voting Process

The equity shareholders meeting will be conducted through video conferencing and other audio-visual means, providing accessibility for all stakeholders.

Strategic Merger Overview

The proposed amalgamation aims to create one of India's top 3 hospital chains, with the company highlighting strong shareholder support. The merger has already received approval from an overwhelming majority of 99.998% of shareholders for the share swap arrangement preceding the merger.

The combined entity is positioned to establish a comprehensive healthcare platform with significant operational scale:

Financial and Operational Benefits

The merger is expected to deliver substantial synergies and operational improvements. The company has identified synergies with an EBITDA upside potential of 10-15%, computed as a percentage of pro-forma EBITDA of the merged entity.

Key strategic advantages include stronger financial, operational and return metrics, significant opportunities for both brownfield and greenfield expansion, multiple synergies to accelerate growth and improve margins, and enhanced clinical excellence capabilities.

Governance Framework

The company has addressed stakeholder concerns regarding governance through a comprehensive framework. Both Aster Promoters and Blackstone have committed to specific governance measures, including waiving director nomination rights when their shareholding falls to 10%. The governance structure includes board committee composition determined in accordance with applicable law, mandatory independent director representation on all committees, and robust check-and-balance mechanisms for committee decisions.

Regulatory Compliance

The meeting notice has been issued under Regulation 30 and other applicable provisions of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The scheme of amalgamation is being pursued under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The company emphasizes that the proposed merger aligns with long-term shareholder interests, combining a strong business case with reasonable valuation and governance rights designed to ensure continued stakeholder alignment.